Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal

Merck moves Alzheimer's drug into big trial after safety review

Source: Reuters - Tue, 10 Dec 2013 01:44 PM
Author: Reuters
Tweet Recommend Google + LinkedIn Bookmark Email Print
Leave us a comment

Dec 10 (Reuters) - Merck & Co said it will advance its experimental Alzheimer's drug into late-stage trials among patients with mild to moderate disease, after an independent monitoring board reviewed its safety and recommended the trial continue to recruit patients.

The data monitoring committee gave its blessing to a far larger trial involving almost 2,000 patients after examining interim safety data from a mid-stage trial of 200 patients who had been treated with the medicine, called MK-8931, for at least three months, Merck said.

The medicine works by blocking an enzyme called BACE that is involved in the production of beta-amyloid, a protein that creates plaques in the brains of people with Alzheimer's disease.

BACE inhibition is considered the most promising new approach to slowing progression of Alzheimer's disease, after other efforts to directly block beta amyloid have failed or fallen short in trials conducted by Pfizer Inc, Eli Lilly and Co and other drugmakers.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Topical content

Latest slideshow

See allSee all
Featured jobs